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Abstract
The identification of microbiological infection is usually a diagnostic
investigation, a complex process that is firstly initiated by clinical suspicion.
With the emergence of high-throughput sequencing (HTS) technologies,
metagenomic analysis has unveiled the power to identify microbial
DNA/RNA from a diverse range of clinical samples (1). Metagenomic
analysis of whole human genomes at the clinical/research interface
bypasses the steps of clinical scrutiny and targeted testing and has the
potential to generate unexpected findings relating to infectious and
sometimes transmissible disease. There is no doubt that microbial findings
that may have a significant impact on a patient’s treatment and their close
contacts should be reported to those with clinical responsibility for the
sample-donating patient. There are no clear recommendations on how
such findings that are incidental, or outside the original investigation, should
be handled. Here we aim to provide an informed protocol for the
management of incidental microbial findings as part of the 100,000
Genomes Project which may have broader application in this emerging 
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 Genomes Project which may have broader application in this emerging 
field. As with any other clinical information, we aim to prioritise the reporting
of data that are most likely to be of benefit to the patient and their close
contacts. We also set out to minimize risks, costs and potential anxiety
associated with the reporting of results that are unlikely to be of clinical
significance. Our recommendations aim to support the practice of microbial
metagenomics by providing a simplified pathway that can be applied to
reporting the identification of potential pathogens from metagenomic
datasets. Given that the ambition for UK sequenced human genomes over
the next 5 years has been set to reach 5 million and the field of
metagenomics is rapidly evolving, the guidance will be regularly reviewed
and will likely adapt over time as experience develops.
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Introduction
Changes in sequencing technology
The emergence of high-throughput sequencing (HTS) over the 
last decade has revolutionised the area of genomic medicine. 
Since 2014-2015, the $1000 genome is a reality2; as human 
genome sequencing becomes more affordable, it is likely to 
play an increasing role in routine clinical practice.
Structure of the 100,000 Genomes Project
The Genomics England 100,000 Genomes Project reflects 
the increasing role of HTS and genomic medicine in routine 
clinical practice. It was designed to underpin development of 
clinical practice in the National Health Service (NHS) of the 
United Kingdom by fostering the genomics-based develop-
ment of personalised and precision medicine. The project further 
strengthens the synergy between clinical investigation and 
research, aiming to accelerate participants’ benefit from HTS 
of their genomes. Recruitment was completed in 2018 and 
the de-identified (or depersonalised as all direct identifiers are 
removed from the dataset) sequence database is now available 
to groups of researchers forming the Genomics Clinical 
Interpretation Partnership (GeCIP) domains3. On October 2018 
an expansion of the 100,000 Genomes Project was announced 
to see 1 million genomes sequenced by NHS and UK biobank 
within the following 5 years, while the overall ambition for 
UK was set to 5 million genomes within the same 5-year 
period4.
Participants (numbering approximately 85,000) in the 100,000 
Genomes Project were NHS patients with a rare disease 
(plus in some cases family members) and patients with cancer. 
They were recruited by a healthcare professional involved in the 
patient’s clinical care and referred to 13 specialised NHS 
Genomic Medicine Centres. Genome sequencing was conducted 
to search for information that could potentially benefit the patient 
as well as contributing to research in that disease area. For the 
purposes of this paper, all participants will be referred to as 
patients, as the primary aim of the project is to advance clinical 
care.
Consent and return of findings to participants
The term “health-related findings” is used in the current 
literature to describe a finding made by researchers during 
the course of a study that has potential health or reproductive 
importance to an individual participant5. Amongst these findings 
can be “incidental findings” that are outside of the focus of the 
original investigation. The ethical issues raised by such findings 
have been considered extensively by other expert groups, whose 
opinions we have reviewed5–11. Participants in the 100,000 
Genomes Project are already having primary findings directly 
related to their condition reported to them. At the time of 
recruitment, they could also choose whether to opt-in or not to 
receive “additional findings”, namely those for a limited set of 
conditions not connected directly to their primary diagnosis. 
Table 1 lists the conditions for which additional findings might 
be reported, although participants were also told this list might 
change as evidence about such findings accumulated.
This specified list of conditions was based on generally agreed 
requirements5: these are recognized, serious conditions where 
a treatment approach exists that has been proven to be effective. 
In contrast, “incidental findings” were defined as findings that 
were generated without intent by the whole process rather than 
specifically sought. Simply because they have not been looked 
for does not mean they are not important; however, searching 
for every potential finding that might or might not be 
significant to the individual is time-consuming, expensive and 
may not produce beneficial information. Genomics England, in 
choosing its list of additional findings, has narrowed down 
the possible list of findings, consideration is now needed as to 
whether incidental microbial sequence findings constitute 
situations that should be communicated to participants and their 
clinical teams.
Identification of microbial DNA as a secondary consequence 
of human genome sequencing
The 100,000 Genomes Project uses biological samples (whole 
blood or sputum) to determine the germline genome of each 
recruited patient (as well as tumour tissues for determining 
the cancer genome where applicable). The project takes a 
‘re-sequencing approach’, whereby fragments of human DNA 
are read with HTS and subsequently mapped to an existing 
reference sequence of the human genome. Every piece of 
DNA present in the sample is equally likely to be read by HTS 
approaches. The indiscriminate reading of within-sample DNA 
suggests that nucleic acid unrelated to the human genome will 
Table 1. Genomics England additional findings list.
Bowel cancer predisposition:
MLH1 (adult only), MSH2 (adult only), MSH6 (adult only), MUTYH (adult only)
APC (adult and child)
Breast and ovarian cancer predisposition:
BRCA1 (adult only), BRCA2 (adult only)
Other cancer predisposition:
VHL (adult and child), MEN1 (adult and child), RET (adult and child)
Familial hypercholesterolaemia:
LDLR (adult and child), APOB (adult and child), PCSK9 (adult and child)
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also be included in the raw reads (unmapped to the human 
reference genome). Recognising that the presence of non-human 
DNA from microbes (bacteria, fungi, protozoa and viruses) 
could have clinical significance in specific circumstances, the 
Integrated Pathogen and Mobile Element GeCIP domain was 
formed in order to extract metagenomic microbial DNA from 
the 100,000 Genomes Project data. Whether the identification 
of microbial sequences in these data should be reported to the 
patient and the attending clinician to trigger a clinical investiga-
tion is a complex decision involving bioinformatic, technical, 
clinical and ethical considerations.
Early detection and treatment of harmful and potentially 
transmissible infections could help to improve health outcomes 
for participants and their close contacts. There is a balance 
between the need to have a robust reporting strategy in 
place for cases where participants and their clinical teams would 
benefit from receiving the information, versus avoidance of 
generating unnecessary investigations, anxiety and cost that 
could be generated by spurious, irrelevant or misleading results. 
Previous experience has suggested that medically relevant, 
actionable findings were found in between 0.8% and 5% of 
research participants12,13.
Exploring the nature and significance of microbial reads 
arising from metagenomic datasets is important. In response 
to the request of Genomics England Science Advisory 
Committee, we have drawn together colleagues with experience 
in medical microbiology and infectious disease, sequencing, 
bioinformatics and bioethics, to examine the issue of incidental 
microbial findings in human genomic DNA metagenomic data. 
Specifically, we have considered:
•     The potential additional findings that may be generated 
by the Integrated Pathogen and Mobile Element GeCIP 
domain;
•     The uncertainties associated with technical validity of 
pathogen detection within human samples;
•     The practical criteria that might be applied to help define 
clinical ‘actionability’;
•     The findings that should be communicated to the patient 
and to their clinical team, and in which circumstances this 
should occur.
•     Findings which do not justify or need onward 
communication.
Through these discussions, we have advised on a process for the 
reporting of additional microbial findings. Our strategy seeks 
to strike a delicate balance – enabling patients to receive the 
best care based on available knowledge while not burdening 
them or their clinical teams with information that does not 
inform investigation, treatment or prognosis, and might result in 
unneeded additional interventions. Given that, as already stated, 
this project deliberately inhabits the hybrid territory between 
research and clinical practice, some of the difficulty in 
striking this balance arises from translating research findings 
(and a lack of large-scale evidence) into clinical practice.
Considerations made by the expert committee
The ability of metagenomic approaches to identify 
pathogens in clinical samples
Technical assessment of the accuracy of metagenomic 
sequencing for diagnosis of infection. Diagnosis is usually 
based on a combination of clinical evaluation supported by 
laboratory testing and/or other investigations (e.g. imaging). 
A clinical investigation assesses the possibility that a patient 
indeed has or doesn’t have a specific disease. The pre-test 
odds for a patient having a disease are usually provided by 
epidemiological studies (e.g. cross-sectional studies of disease 
in a specific population)14. For example, the risk of developing 
breast cancer within the age group 30-40 is 1 in 228 (data from 
https://www.breastcancer.org); thus a patient with no symptoms 
aged 35 has a pre-test odds for breast cancer of 1/227. These 
pre-test odds can be modified by the initial clinical assessment, 
which includes medical and family history and identification of 
signs and symptoms. Targeted laboratory testing then further 
modifies the pre-test odds. Once a positive test result has been 
acquired, a likelihood-ratio value of the positive test will upgrade 
the pre-test odds of having the disease as follows: 
Post-test odds = pre-test odds × likelihood ratio
The likelihood ratio of a positive test is formally calculated by the 
ratio of the sensitivity of the test divided by (1-specificity) 
Likelihood ratio = sensitivity/(1-specificity) (A)
Thus, in order to evaluate the ability of metagenomics findings 
to diagnose infectious disease in genomic data (including the 
100,000 Genomes Project data) we would ideally evaluate the 
Likelihood ratio of the approach. According to Formula A an 
assessment of sensitivity and specificity of the approach 
compared to existing clinically validated approaches is required. 
It is anticipated that the approach will not have the same 
values of sensitivity and specificity for all pathogen findings, 
and output will be modified by other variables such as host 
immunity, sample type, and pathogen burden.
Comparison of metagenomic data to existing clinically vali-
dated methods for pathogen identification at the species level. 
Here we consider the part of identifying a pathogen that is 
classifying it into a specific species. Sequencing followed by 
phylogenetic reconstruction is a powerful approach to classify 
new species as well as identify known species15,16. Alternative 
traditional approaches include: a) microbial cultures, b) nucleic 
acid tests (e.g. real-time PCR), c) identification of antigens 
and/or antibodies. The value and power of metagenomic data 
in identifying viruses has been recognized and proposed to be 
adapted from the International Committee of Taxonomy of 
Viruses (ICTV)17. It is thus expected that under specific 
circumstances genomic data can provide a reliable way to identify 
a pathogen at the species level.
Specificity and sensitivity of metagenomic data for identification 
of micro-organisms at the species level. Data generated as part of 
the 100,000 Genomes Project are comprised of “reads” (nucleotide 
sequences) of ∼150 bp in length3. In theory, if the 150-bp-read 
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shares high genetic similarity to a pathogen reference genome, 
this could represent highly specific identification of the pathogen. 
However, if the same read shared high similarity with another 
species, then the resolution at species level would be unreliable. 
A phylogenetic analysis of the candidate 150-bp-read sequence, 
together with reference sequences of closely related species on 
potentially homologous (or highly similar) genomic regions, 
could robustly indicate whether there is sufficient information to 
classify the sequence for a specific organism18.
The sensitivity of the metagenomic approach (the probability 
of identifying the organism given its existence in the biological 
sample) is difficult to estimate. HTS is a theoretically unbiased 
approach, and we do not have any expectation that pathogen 
DNA molecules would have a different probability of being 
sequenced compared to human DNA molecules; however, this 
is based on the relative abundance of each sequence. Thus, in a 
mixture of pathogen/human DNA molecules in which human 
DNA accounts for the vast majority of sequence material, then the 
possibility of sequencing a pathogen sequence could be very low. 
This results in a low sensitivity of the approach for detecting the 
organism, as demonstrated by previous studies19, but depends on 
the sample type and the burden of the organism. Some empirical 
examples are mentioned below:
a)     The cerebrospinal fluid (CSF) sample of a person with 
pneumococcal meningitis could contain a high ratio of 
organism-to-human DNA ratio because the genomic 
DNA load of the CSF is lower than blood or tissue 
samples (low cell count which increases in bacterial 
meningitis), and the bacterial load of pneumococcal 
meningitis is usually high.
b)     HIV infection with low pro-viral loads in blood stream 
would have a low ratio of organism-to-human reads, since 
whole blood has a high host genomic DNA load.
c)     Adenovirus in respiratory secretions could be vastly 
outnumbered by commensal (bacterial) flora and 
human DNA.
Based on these considerations, it is feasible that metagenomic 
data have the potential to provide powerful identification of a 
pathogen at the species level and if performed appropri-
ately the identification of the micro-organism could approach 
100% specificity17. In this case, identification is defined 
as the process of correctly assigning the species ID of an 
organism, which is only one component of the diagnostic 
process of identifying a pathogen that is clinically significant. 
The HTS approach as a diagnostic process may often suffer 
from low sensitivity, but due to the ultra-high specificity of the 
data it may still be valuable for diagnostic purposes: When spe-
cificity is 1, the likelihood ratio of the test becomes infinite 
regardless of the sensitivity of the approach (see Formula A), 
thus the certainty for the ID of the micro-organism is maximised.
The use of short sub-genomic sequences (e.g. 150 bp) in 
resolving pathogen species is expected to be more accurate in 
viruses than in bacteria and fungi. This is based on a number of 
features of viral genomes:
1)     Viruses overall evolve fast20, and phylogenetic 
information in homologous, non-repetitive regions can 
be sufficient to resolve evolutionary relationships even 
within the same species. In contrast, mutation rates 
(when considered per nucleotide) in bacteria and 
fungi vary a lot, with many important genes being 
under strong negative selection. Thus, short sequences 
(150 bp) can be insufficient in many cases for 
resolving evolution at the species level (e.g. ribosomal 
RNA21).
2)     Only large-genome (>30,000 bp) viruses harbour 
transposons (repetitive regions); small genome viruses 
(the majority of pathogenic viruses) have their genomes 
packed in a way that transposable elements would be a 
rare phenomenon. On the other hand, repetitive regions 
are present in both bacteria and fungi.
3)     Non-homologous regions of viral genomes (e.g. short 
tandem repeats, mononucleotide stretches) have very low 
content of evolutionary information, thus they cannot 
be used for resolving species. Small viruses do not have 
long stretches of such regions, while they are commonly 
present in both bacteria and fungi.
Based on the above considerations, 150bp sequences derived 
from viruses of genomes <30,000 bp should frequently yield 
sufficient information to resolve identification at the species 
level. On the other hand, larger viruses (such as Herpesvi-
ruses), have low-complexity areas in the genome that could be 
confused even with the human genome (e.g. short-tandem 
repeats with telomeres). Even more difficult is the discrimina-
tion between bacterial or fungal species; identification of these 
organisms at the species level based on short reads can be 
difficult, unless the identified 150-bp read comes from specific 
genomic regions, or can be reconstructed with other sequence 
fragments to represent a longer continuous portion of pathogen 
genome.
Specific recommendation: The identification of pathogens 
within HTS can be highly specific, but may frequently be 
insensitive, and the clinical utility of these findings has not been 
validated, yet. Therefore, prospective analysis of pathogen 
sequences from metagenomic analyses is needed to determine 
likelihood ratios for diagnosis of infectious diseases. It is also 
noted that this might not be feasible (or clinically useful) 
for all available pathogens, thus we propose to priori-
tize pathogens according to their potential for clinical ben-
efit. Considerations on the potential clinical benefit of pathogens 
should be examined by an Infectious Disease Expert subgroup. 
Microbiological considerations beyond identification of 
pathogen at species level
The species identification of a pathogen is not sufficient to 
provide a clinical diagnosis. In order to upgrade the identification 
of a pathogen to a clinically important result we need to:
1)    Evaluate sources of bias/uncertainty in the metagenomic 
process involving a pipeline from sample collection 
through the wet lab process and bioinformatic analysis 
(outlined in 3.2.1);
2)    Evaluate the finding under a clinical microbiological 
framework (outlined below in Evaluation under a clinical 
microbiology framework);
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3)    Consider the result that has been obtained in light of the 
clinical sample, the patient condition and underlying 
diagnosis, and other relevant results (routine observa-
tions, imaging, laboratory parameters) (outlined below in 
Evaluation under a clinical microbiology framework).
Sources of uncertainty in the generation and interpretation of 
metagenomic data. Pathogen metagenomic findings should be 
examined as a laboratory procedure, thus we need to consider 
potential sources of error.
(i) Pre-analytical errors: Genomics England samples have been 
collected according to a validated procedure for human genome 
sequencing, including aseptic technique which should result in 
minimal pre-analytical errors for pathogen isolation. However, 
the approach has been validated for collection of human DNA, 
not for microbial diagnostics. Thus, there is still potential for 
contamination of samples by micro-organisms (most likely 
bacteria or fungi). Organisms that are commonly found in the 
environment or as part of human flora are more likely to be 
found due to pre-analytical contamination, but contamination 
of reagents used throughout the wet-lab process has also been 
described22,23 (see also Extended data, extended text24).
(ii) Analytical errors: these errors are introduced either as a 
result of the sequencing process or based on bioinformatic 
analysis. Due to the high fidelity of Illumina sequencing, the 
probability of the former is low. As discussed in below in 
Relevance of pathogen findings with patient’s recruitment and 
well-being, metagenomic data can result in specific identifica-
tion of a pathogen but can also lead to indeterminate conclusions 
about the presence of a specific micro-organism (also discussed 
in Extended data, extended text24 and below in Relevance of 
pathogen findings with patient’s recruitment and well-being). 
We thus suggest the following criteria to be taken into account 
when considering the identification of a pathogen based on 
metagenomic data:
a) Sequence specificity: In order to confirm that the sequence of 
a microbe is present in the unmapped HTS data (i.e. data that 
cannot be aligned with the human genome), the query sequence 
should be uniquely mapped to the microbial genome. This can 
be investigated through a standard search (e.g. BLAST25) of the 
query sequence against a full database of existing microbial 
sequences, which should retrieve the specific microbe as the top 
hit with a significant divergence from the second hit. This should 
be followed up by phylogenetic analysis to confirm clustering 
of the query sequence within the identified species, supported 
by high bootstrap values (>75) (phylogenetics are also discussed 
above in The ability of metagenomic approaches to identify 
pathogens in clinical samples).
b) Number of sequences: Many microbes are commonly found 
in the environment or as part of normal human flora. Even 
with robust aseptic technique, the procedure of obtaining a 
blood or tissue sample is potentially subject to contamination. 
Such contamination should usually be low-level, and thus 
quantitative support (e.g. number of DNA sequences) may help 
to differentiate between low-level contamination vs. the presence 
of a genuine infecting agent. Considerations about environmental 
contamination of the received sample in the post-sampling 
pre-analytical period have been reported26 and should also be 
taken into account27. Cross-contamination during the different 
stages of laboratory processing, from extraction to sequencing, 
can result in ascribing a result to the wrong sample. Cross- 
contamination can be intra-run or inter-run thus knowledge of 
pathogens normally processed by the lab can be useful. One way 
to test for potential contamination is by performing phylogenetic 
analysis of retrieved pathogen sequence data in the same 
run and immediate previous runs: unexpected closely related 
pathogen sequences between unrelated participants would be 
evidence of post-sampling contamination28. With respect to 
defining a threshold of number of reads above which the identi-
fication of the microbe in the sample is considered very likely, 
we comment below in Evaluation under a clinical microbiology 
framework.
Evaluation under a clinical microbiology framework. Results 
should be evaluated based on the source of the biological 
sample, recognising the presence of commensal and/or 
environmental flora in some sample types (e.g. stool, sputum) 
versus the anticipated sterility of others (e.g. blood, CSF, joint 
aspirate). Thus, it is important, especially for non-sterile sites, 
to consider the need for quantitative thresholds above which 
we may consider that the presence of specific microbial 
sequences is more likely to suggest the presence of clinical 
infection.
The presence of microbes that are known to be part of normal 
flora should be interpreted cautiously; the combination of 
background information (e.g. biological sample, clinical context) 
would be required to determine clinical significance. For 
example, microbial cultures sometimes require the quantifi-
cation of the microbe to help distinguish between contami-
nation or low-level (non-pathogenic) microbial colonization 
(e.g. sputum or urine cultures, in which a typical threshold 
of >105 cfu/ml is typically assigned for clinical significance). 
With respect to distinguishing colonization from an active 
infection, some microbial cultures require quantification of 
other features of the sample, such as number of white blood 
cells. The latter can help to distinguish between microbial 
infection and benign colonization. Such clinical sample data 
are missing from Genomics England samples, thus clinical 
interpretation for non-sterile samples needs to be examined very 
cautiously.
Data generated as part of the 100,000 Genomes Project are 
strictly genomic DNA. Thus, RNA molecules with no DNA 
stage (such as RNA viruses, not including retroviruses) should 
not currently be reported as they are most likely to represent 
artefacts. However, in selected cases where there have been 
reports of reverse transcription of microbial RNA from 
active human transposons, such as for example in HCV29, the 
identification could be reported to the clinician/patient as it 
might signify the existence of an integrated virus in the context 
of a true infection.
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Timing of data availability. The timing of data analysis 
generated by the 100,000 Genomes Project typically occurs 
weeks to months after the sampling process. On this basis, we 
determined that all microbes identified and known to be 
responsible for acute-syndrome pathogenesis without chronic 
sequelae should not be reported to the patient or clinician, as 
their identification would not contribute to the clinical manage-
ment of the patient. For example, bacteraemia is usually an acute 
short-term illness; the identification of bacteria in blood 
samples that have been drawn 6 months before the analysis is 
rarely likely to provide any clinical benefit to the patient. In 
contrast, microbes associated with chronic syndromes could 
provide a benefit if reported to the clinician and the patient, as 
they might remain undiagnosed and continue to contribute to 
pathology.
Finally, microbes of public health importance could poten-
tially trigger an epidemiological investigation. The timing of the 
identification is crucial in cases of public health importance; 
thus, it should be considered whether an epidemiological 
investigation several months after initial identification is likely to 
have a benefit, and to weight this against the resources required 
for an investigation, and potential unnecessary anxiety to the 
public patient.
Prevalence of a microorganism in human populations. 
Under the presupposition that participants’ symptoms were not 
considered relevant to infectious diseases, identification of 
pathogens that are highly prevalent in the general population 
provide a small margin of diagnostic benefit. The pre-test odds 
of having the infection is high (i.e. even before our metagenomic 
analysis), thus an increase of these odds as a result of the 
metagenomic findings is unlikely to enable a diagnostic 
benefit. For example, a pathogen such as Epstein–Barr virus has a 
prevalence of 90% in some populations. A test would update the 
a priori probability of infection from 0.90 to close to 1 (i.e. 10% 
increase of the probability of having the infection). Given the 
uncertainties in the metagenomic approach (i.e. follow-up 
clinical test verification is required), the probabilistic gain in 
diagnosis is very low. If the finding is actually important for 
patient’s well-being, then high pre-test probabilities should have 
necessitated clinical investigation especially through general 
population screening recommendations.
Pathogenicity of a microorganism. Reporting low-pathogenicity 
organisms (e.g. pathogens which are unlikely to impact the 
patient in the long-term) is less likely to enable a benefit, 
although this may depend on the clinical status of the individual 
(see also Clinical context of the research participant, below). 
Pathogenicity varies according to host context, and the type of 
sample from which the organism is identified. However, some 
organisms (e.g. HIV) are considered pathogenic irrespective 
of the sample type or clinical details of the host, and their 
identification should trigger a clinical investigation regardless 
of the patient’s clinical status. On these grounds, reporting 
highly pathogenic organisms is likely to be beneficial.
Potential for treatment and/or prevention. In the absence 
of guidelines for treatment/prevention of specific infections, 
reporting them is unlikely to enable a clinical benefit (e.g. 
for most viral infections within the community). However, if 
knowledge of the presence of the microbe is important for the 
prognosis within the individual host, or could have a benefit to 
sexual partners, other close contacts and the unborn child, this 
could be reported even in the absence of potential antimicrobial 
intervention.
Clinical context of the research participant. Co-morbidities, 
including immunosuppression, may be a relevant consideration. 
Many infections in immunocompetent individuals (including 
most viral infections) are less likely to have long-term clinical 
significance or underpin any treatment decisions.
Specific Recommendation: We propose the formation of an Infec-
tious Disease Subgroup comprised of clinical microbiologists 
and infectious disease specialists. The purpose of this subgroup 
was to evaluate potentially important microbial findings 
through the process adopted by Genomics England for reporting 
additional findings before communicating to the clinician. 
The Infectious Disease Subgroup reviewed an extensive list of 
potential human pathogens (Extended data, Pathogen list24) 
and proposed which metagenomics pathogen findings should 
be followed up in this way (see below, Specialist considerations 
made by the Infectious Disease Subgroup).
Relevance of pathogen findings with patient’s recruitment 
and well-being
Reporting primary and additional findings. At present, there 
are insufficient data to determine the extent to which certain 
microbes could be directly related to the patient’s index 
condition or those under the additional findings list. While 
exposure to microbes is a major cause of cancers – epide-
miological data suggested that in 2002 17.8% of cancers 
were caused by viral (∼12%), bacterial (5.6%) and helminth 
(0.1%) infections30 – establishing primary causation may be 
much more difficult. The International Agency of Research for 
Cancer30 has categorized biological agents into four categories 
according to evidence supporting their role in causing cancer 
(Table 2).
The subgroup considered whether category 1 microbes should 
be reported to cancer patients as they could potentially be 
considered as “primary findings”. According to information 
provided to patients during the consent, the majority of partici-
pants should have understood that a “primary finding” would be 
a feature of the human genome, and may not expect their data 
to include microbial sequences. Crucially, many such agents are 
Table 2. Carcinogenicity of biological agents29.
Group Carcinogenicity
1 The agent is carcinogenic to humans
2A The agent is probably carcinogenic to humans
2B The agent is possibly carcinogenic to humans
3 The agent is not classifiable as to its carcinogenicity 
to humans
4 The agent is probably not carcinogenic to humans
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ubiquitous in most human populations, and evidence of exposure 
to a micro-organism would not inform management of an 
established cancer (as exemplified by herpesviruses and human 
papillomavirus).
Specific recommendation: At present, there is insufficient 
evidence that oncogenicity of a microbe, apart from 
hepatitis B virus (HBV) and hepatitis C virus (HCV), should 
mandate reporting of the identification of that microbe to 
cancer patients.
Reporting incidental microbial findings. As discussed, 
incidental microbial findings may have significant importance 
for an individual. This has been the case for non-microbial 
(genomic) incidental findings, for example mutations 
associated with cystic fibrosis or Huntingdon’s disease in a 
cancer patient are not related to the reason that the patient 
was recruited, but can be important for their own well-being 
and/or that of their family and future offspring. If an inci-
dental finding is discovered (microbial or not-microbial) 
decisions will need to be made whether it is important to the 
health of the individual and whether and how this should be 
communicated.
Specific recommendation: We recommend evaluating poten-
tially important incidentally-discovered pathogen metagenomics 
findings for their impact on the health and well-being of 
participants and their families (i.e. a personalized assessment of 
the finding given information available for the participant).
Bioethical considerations and consent
When a proportion of participants agreed to receive “additional 
findings” that are not relevant to their primary condition, it is 
unlikely that they considered that this might include the 
identification of infectious agents that are not directly related to 
their index diagnosis. For future studies in which metagen-
omic data are collected, consent discussions should provide a 
range of potential additional findings (including detection of 
pathogens) and emphasise that communication will usually be 
decided by a multidisciplinary team, based on both evidence 
and risk/benefit assessment.
Some participants chose not to receive any additional find-
ings. However, experience has shown that participants often 
couldn’t accurately recall what decision they had made, but they 
expected clinically useful information to be reported back. 
One approach to maintaining up-to-date valid consent could be 
to re-contact participants at regular intervals to check their 
wishes; another option would be to ensure that future consent 
was broad enough to cover this sort of possibility. Providing 
patients with general data about study results may prompt 
individuals to re-examine their choice. Evidence from Genomic 
Medicine Centres suggests that many people do not recall what 
decision they made regarding additional findings, nor that they 
understood what might be revealed in this category (personal 
communication).
Specific recommendation: Although there is insufficient 
evidence that opting out from feedback of additional findings 
constitutes a valid advance refusal for infectious disease 
incidental findings, if the findings may have a health-related 
benefit, they should be passed to a clinician for further 
examination.
Conclusion of Expert Committee
Given the high volume of data generated as part of the 100,000 
Genomes Project, clinical microbiology follow-up of every 
potential pathogen finding is not feasible. We thus propose 
filtering out potentially spurious or low priority, clinically 
unimportant results of the metagenomics approach, in order to 
allow the infectious disease subgroup to focus on high-priority 
findings (as recommended in Suggested pathogens to be reported 
for further clinical evaluation).
Specialist considerations made by the Infectious 
Disease Subgroup
Suggested pathogens to be reported for further clinical 
evaluation
The infectious disease subgroup, after considering the domains 
outlined in the preceding sections, unified by considering the 
overall importance of the findings for the participant’s welfare 
and the likelihood of the results being significant to clinical 
management, reviewed an exhaustive list of potential human 
pathogens (Extended data, Pathogen list24).
They concluded that, for the time being, the following list of 
pathogens should be flagged as potentially important for the 
participant’s welfare and that of their close contacts:
1) HIV
2) HBV
3) HCV
4) Human T-Lymphotropic Virus
A summary of the considerations is provided in Table 3. 
Infections of these viruses comply with our fundamentally 
agreed criteria of being persistent, serious, treatable (actionable) 
and/or transmissible. They are also unlikely to be the result of 
environmental contamination (these pathogens replicate within 
human cells) thus the pre-analytical source of bias is minimized. 
Finally, their genomes are sufficiently complex and distant 
from other non-pathogenic microbes so that their metagenomic 
identification is likely to be reliable.
Clinical evaluation, audit and communication with patient
When the identification of the pathogen is considered highly 
likely, then ideally it should be evaluated by a clinical 
microbiologist who would put this finding into appropriate 
context before discussion with the patient’s attending clinician 
(Figure 1). Until metagenomics findings have been properly 
validated producing outputs sufficiently simplified for clinical 
microbiologists, the role of the clinical microbiologist will 
be covered by the Infectious Disease Expert Subgroup. 
Given the position of clinical microbiologists in NHS infec-
tious disease services, we propose the following process of 
microbiological investigation:
a)    evaluation of pathogen findings and if appropriate request 
additional validation (such as independent bioinformatic 
analysis to be performed on the data),
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Table 3. Summary of considerations for reporting metagenomic findings.
Consideration Point of 
Relevance
Criteria for reporting to 
research participant
Recommendation
1. Need to discriminate between 
environmental contamination, and true 
presence of a microbe in a clinical 
sample;
Pre-analytical There must be reasonable 
certainty that an organism 
identified is a pathogen
Organisms that may reflect environmental 
contamination should not be reported.
2. Need to discriminate between 
commensal flora (harmless to the host) 
vs pathogenic organisms (associated 
with a disease phenotype);
Pre-analytical 
Clinical 
evaluation
There must be reasonable 
certainty that an organism 
identified is a pathogen
Organisms that may represent commensal flora 
should not be reported. Reporting should be 
reserved for organisms that cause serious and 
persistent infection.
3. Long time delays may occur 
between acquisition of a clinical 
sample and identification of microbial 
reads through the metagenomic 
pipeline;
Clinical 
evaluation
Identification of a pathogen 
must occur within a period 
deemed timely for appropriate 
clinical intervention
After a time lapse of weeks/months, feedback 
to the participant is not relevant for the majority 
of pathogens. Reporting should be reserved for 
conditions that influence treatment decisions.
4. Quality controls are required for 
metagenomic sequencing of pathogen 
DNA;
Analytical Sequencing platform is 
currently not validated for 
clinical diagnostics, so the 
majority of pathogen sequence 
data should not be reported to 
participant
Over time, consider developing positive 
controls for microbial identification from 
metagenomic sequencing platforms. Sterility of 
sample handling and sequencing environment 
needs to be assured.
5. Quality controls required for 
bioinformatic processing of 
sequencing data;
Analytical Bioinformatic platform is 
currently not validated for 
clinical diagnostics, so the 
majority of pathogen sequence 
data should not be reported to 
participant
Over time, pathogen-specific and tissue-
specific algorithms are required (e.g. to specify 
what number and % of reads, length and depth 
of coverage of a micro-organism’s genome) to 
report its presence in the sample. A designated 
pathogen database of reference genomes 
should be developed
6. Identification of a pathogen may 
have implications for contacts of the 
participant;
Clinical 
Evaluation
Confirmation of a specific 
pathogen would have 
consequences for testing/
treating family members or 
sexual contacts
Identification of blood-borne viruses should be 
reported, as contacts/family members should 
be offered screening ± treatment if infection is 
confirmed
7. Special considerations may arise 
if biohazard organisms are identified 
or reported (potential impact on 
laboratory staff, patient’s clinical 
teams, family members, and the wider 
community);
Clinical 
Evaluation
There must be reasonable 
certainty that an organism 
identified is a pathogen, has 
been correctly identified, within 
an appropriate time-frame for 
clinical action
Reporting biohazard organisms could cause 
high anxiety and cost affecting a wide 
number of people. Reporting should only be 
undertaken in keeping with points 1–6 above.
8. Need to differentiate between 
results that may have impact for an 
individual patient, versus those that 
could underpin future patient-stratified 
medicine or provide longer-term 
insights into pathophysiology of 
disease
Clinical 
Evaluation
The presence of a micro-
organism should only be 
reported to the participant/
clinician if it will change current 
clinical management.
Organisms that may be important in disease 
pathogenesis (e.g. oncoviruses) should 
be recorded for research purposes but not 
reported back to individual participants.
b)    evaluation of the importance of the findings for the 
patient’s welfare in line with considerations detailed 
in this report,
c)    suggestions with respect to appropriate routine testing for 
validation of the result
Since data are depersonalized for researchers and the 
Infectious Disease Subgroup, but can be linked with specific 
patients through Genomics England, the result, if deemed 
sufficiently valid, will then be communicated with specific 
recommendations for follow-up to Genomics England. Genom-
ics England has designed specific procedures for reporting 
additional findings to the clinician who will then have the duty 
of care to schedule appropriate follow-up with the patient and 
planning further clinical investigation as required.
Suggested future actions
The list of the pathogens will be reviewed by the 100,000 
Genomes Project Infectious Disease Subgroup based on research 
findings from the Integrated Pathogen and Mobile Element 
GeCIP, as well as evidence released by other groups as more 
data become available. The policy and microbial data gener-
ated so far and, in the future, will be kept under regular review 
(suggested as every 6–12 months) by the Infectious Disease 
Subgroup.
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Figure 1. Suggested pathway for reporting potentially important pathogen findings from the 100,000 genomes project projected and 
potentially adapted for other human whole genome sequencing projects. Dotted line shows an optional pathway. Blue=actions taken, 
Green=results obtained, Red=queries made.
Conclusions
High-throughput sequencing has created opportunities to 
advance healthcare. The new genomic medicine service for the 
NHS is founded in the 100,000 Genomes Project. Genomic data 
generated through this process have the potential to be valu-
able in ways that we do not yet fully understand and had not 
Table 4. Overall recommendations.
Recommendation 
number
Recommendation
    1 Pathogen sequences from metagenomic analyses should be analysed prospectively to determine likelihood ratios 
for diagnosis of infectious diseases.
    2 An Infectious Disease Expert subgroup, which should be comprised of clinical microbiologists and infectious disease 
specialists, should be responsible for reviewing the potential clinical benefits of reporting pathogens to clinicians
    3 Based on existing insufficient evidence, oncogenics microbes, apart from HBV and HCV, should not be reported to 
cancer patients.
    4 If findings may have a health-related benefit, they should be passed to a clinician for further examination and 
possible communication to patients
    5 Incidentally discovered pathogen metagenomics findings should be evaluated from Infectious Disease Expert subgroup 
for their potential impact on the health and well-being of patients and their families and whether they should be reported.
    6 The below pathogens should be flagged as potentially important for the participant’s welfare and that of their close 
contacts: 
a HIV (Human Immunodeficiency Virus)
b HBV (Hepatitis B Virus)
c HCV (Hepatitis C Virus)
d HTLV (Human T-Lymphotropic Virus)
    7 This policy and the microbial data generated should be kept under regular review (suggested as every 6–12 months) 
by the Infectious Disease Subgroup based on research findings from the Integrated Pathogen and Mobile Element 
GeCIP as well as emerging evidence from scientific literature.
fully anticipated at the outset. Here, we have considered the 
potential for metagenomics analysis to generate pathogen- 
specific health related findings. We have aimed to strike a 
balance based on current evidence, clinical relevance to par-
ticipants and their families, and burden of uncertain findings 
(Table 4). Sequencing technology has advanced more rapidly 
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than our ability to interpret much of the data that are generated. 
We need to be prepared to reassess and amend our recommen-
dations in the light of new evidence or understanding, ensur-
ing patient and public involvement in our process, and avoiding 
hype or tick box approaches to disclosure.
Data availability
Underlying data
No underlying data are associated with this article.
Extended data
Harvard Dataverse: Extended Text for “Potential for diagno-
sis of infectious disease from the 100,000 Genomes Project 
Metagenomic Dataset: Recommendations for reporting results”. 
https://doi.org/10.7910/DVN/ADJGKX24.
This project contains the following extended data:
•    Extended text.
•    Pathogen list (list of pathogens considered for 
reporting).
Extended data are available under the terms of the Creative 
Commons Zero “No rights reserved” data waiver (CC0 1.0 Public 
domain dedication).
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